Both the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) and the iShares Biotechnology ETF (NASDAQ:IBB)target specific niches of ...

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of ...

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

Scientist says child's death reveals 'serious failures in risk assessment, transparency and institutional oversight' The death of a six-year-old girl after receiving an experimental gene-editing ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The US government's latest proposal to tighten outbound investment restrictions on China, extending scrutiny into the fast-growing biotechnology sector, signals a push to curb American capital's ...

Lixte Biotechnology (ISIN: US53833K1060) develops novel cancer therapies targeting key tumor regulators. North American investors eye its clinical-stage assets amid biotech volatility. Understand the ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...